FDA approves Novavax's Nuvaxovid 2025-2026 COVID-19 vaccine for high-risk populations

NOVAVAX INC

Approved for adults 65+ and high-risk individuals 12-64; only protein-based non-mRNA COVID-19 vaccine available in U.S. for 2025-2026 season.
Shelf life extended from 3 to 6 months for the 2025-2026 formula.
FDA requires two postmarketing studies: a Phase 3 safety/immunogenicity study and a Phase 4 placebo-controlled trial on post-COVID vaccination syndrome.
Sanofi to lead commercialization; Novavax receives tiered royalties on sales.
Clinical data show JN.1 strain induces immunity against multiple JN.1 lineage variants including NB.1.8.1 and XEC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.